Back to results
US 2025/0164486 A1Published application
Method of assessing risk of pml
AssigneeBiogen MA Inc.
InventorsGary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Meena Subramanyam, Tatiana Plavina
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Claims48
A method of evaluating the level of anti-JCV antibody in a sample, comprising:
- (a) forming a first reaction mixture comprising a first aliquot of sample and a substrate on which is disposed HPVLP;
- and
- (b) detecting the level of anti-JCV antibody bound to said substrate on which is disposed HPVLP by detecting a labeled detection reagent bound to anti-JCV antibody bound to said substrate;
- wherein one or both of the following are met:
- (i) 20 ngs to 60 ngs of HPVP are disposed on said substrate and (ii) the ratio of sample to substrate is between 1:50 and 1:30,
- thereby evaluating the level of anti-JCV antibody in a sample.
3 more elements
(canceled)
(canceled)
(canceled)
(canceled)
A method of evaluating a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML), the method comprising:
- determining a JC Virus (JCV) antibody titer expressed as nOD, index or other unit, or other characteristics such as affinity or avidity expressed as percent inhibition in the anti-JCV antibody confirmation assay in a biological sample from the patient, wherein
- if the titer or/and percent inhibition, or function of both values is determined to be above or below a pre-determined level, the patient is determined to be at a lower risk of developing PML, and wherein if the titer or/and percent inhibition, or function of both values is determined to be above or below a pre-determined level, the patient is determined to be at an intermediate risk of developing PML, and wherein if the titer or/and percent inhibition, or a function of both values is determined to be at or above the pre-determined level the patient is determined to be at a higher risk of developing PML, and further provided that either
- (i) determining the anti-JCV antibody titer or percent inhibition in a sample of the patient comprises removing a biological sample from the patient's body or analyzing a sample from the patient, or
- (ii) if the patient is determined to be at a lower risk of developing PML, administering a therapy to the patient.
1 more element
(canceled)
(canceled)
(canceled)
(canceled)
48-85. (canceled)
Dependencies are inferred from the claim text.